These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31300876)

  • 1. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
    Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
    Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
    Barth I; Schneider U; Grimm T; Karl A; Horst D; Gaisa NT; Knüchel R; Garczyk S
    Virchows Arch; 2018 May; 472(5):749-758. PubMed ID: 29654370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
    J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of GATA3 predicts progression in non-muscle invasive urothelial carcinoma of the urinary bladder.
    Kamel NA; Abdelzaher E; Elgebaly O; Ibrahim SA
    J Histotechnol; 2020 Mar; 43(1):21-28. PubMed ID: 31551051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
    Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
    Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
    Tadin T; Krpina K; Štifter S; Babarović E; Jonjić N
    Pathol Res Pract; 2014 May; 210(5):279-84. PubMed ID: 24553301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.